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Abstract
Background: Due to risk and response adapted treatment strategies, more than 80% of newly diagnosed classical
Hodgkin lymphoma (HL) patients can be cured, and become long-term survivors. However, a high proportion of
survivors suffer from treatment-related long-term side effects such as secondary malignancy, organ failure,
persistent fatigue and psychological distress. The aim of this study was to evaluate psychological distress and its
risk factors among our HL survivors.
Methods: One hundred sixty-three (50% female) adult HL survivors were contacted between January 1, 2012
and march 31, 2015 in our outpatient centre. The patients were asked to complete a standardized, validated,
self-administered Hungarian questionnaire with demographic questions and the following scales: Hospital anxiety
and depression scale (HADS14), general health questionnaire (GHQ12), sense of coherence (SOC13) perceived stress
scale (PSS4), dysfunctional attitude scale (DAS17). Disease and treatment data were acquired from hospital records.
Results: Majority of HL survivors are in early adulthood, our most important goal should be to return them to
normal life after their lymphoma is cured. The employment status at the time of survey seemed to be crucial
so patients were divided into either active (n = 93) or inactive (n = 47) group. Retired survivors (n = 19) were
excluded from the subgroup analysis. Psychological distress was significantly lower in active patients. Multiple
logistic regression analysis showed significant differences between the inactive and active subgroups, such as age
at diagnosis (≥30 years or below, p = 0.001), education level (below college vs. college, p = 0.032) and treatment
related long-term side effects (yes vs. no, p < 0.001). Predictors for treatment-related long-term side effects are
female gender (p = 0.011), chemotherapy protocol (ABVD vs. other, p < 0.001).
Conclusions: Our data suggest that employment status and treatment-related long-term side effects play a critical
role in the health related quality of life outcome among Hungarian HL survivors.
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Background
Due to risk and response adapted treatment strategies,
more than 80% of newly diagnosed Hodgkin lymphoma
(HL) patients at any stage can be cured, and are ex-
pected to be long-term survivors [1–3]. The majority of
HL patients are in early adulthood (median age about
30 years), so the quality of life after treatment closure is
of fundamental importance. Lymphoma survivors are
live longer, and consequently are at risk of experiencing
adverse psychical and psychosocial side effects for lon-
ger periods of time due to their disease and its treat-
ment [4]. Treatment related long-term side effects such
as secondary malignancy, or organ failure reduces the
quality of life and life expectancy of survivors. There is
a growing number of promising studies focused on sur-
vival related issues in former HL patients, mainly address-
ing overall health-related quality of life (HRQoL) [5].
HRQoL as a multidimensional construct is based on the
World Health Organization’s definition of health incorp-
orating physical, mental, and social aspects of health [6].
HRQoL may be impaired due to treatment-induced or-
ganic dysfunctions, psychological consequences, fatigue,
persisting gonadal and cognitive dysfunction, difficulties
in social and role functioning in HL survivors. HRQoL is
determined based on patient reported outcomes [7]. The
purpose of our study was to evaluate the frequency of psy-
chological distress and its risk factors among HL survivors
based on our single centre experience.
Methods
Subjects and data collection
A cross-sectional survey was conducted at the Department
of Hematology of the University of Debrecen. We
designed the study for approximately 150 from the 301
regularly followed up patients. Exclusion criteria were
age under 18 years at the time of survey and a lack of
signed informed consent. 170 patients were asked to
participate in our study. The refusal rate was below 5%.
Altogether, 163 adult HL survivors were identified be-
tween January 1, 2012 and March 31, 2015 in our out-
patient clinic whose diagnosis of HL was established
between January 1, 1969 and July 1, 2013. Diseases diag-
nosed before the initiation of HL treatment were defined
as comorbidities, whereas treatment related side effects
were defined as conditions diagnosed in the follow-up
phase after HL treatment based on hospital records of the
patients.
Treatment protocols
Primary chemotherapy basically involved CV(O)PP (cyclo-
phosphamide, vinblastine [vincristine], procarbazine and
prednisolone) before. After 1990, COPP/ABV (cyclophos-
phamide, vincristine, procarbazine, prednisolone/adriamy-
cin, bleomycin and vinblastine) was used. Since 1999, the
ABVD (adriamycin, bleomycin, vinblastine and dacarba-
zine) protocol has been most frequently applied. In cases
of relapse, treatment involved BEACOPP (bleomycin,
etoposid, adriamycin, cyclophosphamide, vincristin, pro-
carbazine and prednisolone), DHAP (dexamethasone,
cytarabine and cisplatin), or CEP (CCNU, etoposide,
chlorambucil and prednisolone) regimens. Radiotherapy
of the involved or extended field, mantle, inversed Y or
(sub)total nodal type was administered by a telecobalt
device before 2000 and more recently by a linear acceler-
ator. Extended and involved field radiotherapy were used
before (mean dose, 40 Gy) and after 1998 (mean dose,
33 Gy), respectively (Table 1).
Questionnaires
HL survivors were asked to complete a standardized,
self-administered and validated Hungarian question-
naire, which included items on socio-demographic sta-
tus (place of residence, marital status, educational level,
employment, important life events after lymphoma
treatment) and psychiatric treatment (date and type of
medication) at the time of diagnosis, as well as the
scales listed below. Data on the disease and its treat-
ment were based on hospital records.
The Hungarian version of the Hospital Anxiety and
Depression scale (HADS-14) has been used in studies
of distress among cancer patients in general. Each of
the 14 items is scored on a 4-point scale (0–3). Sum
scores for the anxiety and depression subscales are cal-
culated by simple addition. The constructors of HADS
recommended two possible cut-offs (8 or higher or 11
or higher on either scale) for case definition. In this
study, caseness refers to the lower cut-off [8, 9]. Due to
printing error item 10 in the HADS questionnaire was
missing answer 2 and 3.
The General Health Questionnaire (GHQ-12) is the
most extensively used screening instrument for common
Table 1 The treatment protocols based on the stage of disease
Treatment Number of patients
Stage I. Stage II. Stage III. Stage IV. All
ABVD/EBVD + RT 3 52 9 8 72 (51.5%)
ABVD/EBVD – RT 0 5 9 9 23 (16.5%)
COPP/ABVD + RT 1 3 12 0 16 (11%)
COPP/ABVD – RT 0 0 5 2 7 (5%)
CVPP + RT 1 6 4 1 12 (9%)
CVPP – RT 1 0 2 0 3 (2%)
Other 1 2 4 0 7 (5%)
A(E)BVD: adriamycin (epirubicin), bleomycin, vinblastine and dacarbazine;
CV(O)PP: cyclophosphamide, vinblastine [vincristine], procarbazine and
prednisolone; COPP/ABV: cyclophosphamide, vincristine, procarbazine,
prednisolone/adriamycin, bleomycin and vinblastine; Other protocols include
MOPP: mustargen, vincristine, procarbazin, prednisolone, OEPA: vincristine,
etoposide, prednisone, and doxorubicin
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mental disorders, in addition to being a general measure
of psychiatric well-being. Each item is scored on a 4-point
scale (corresponding to a symptom present: ‘not at all’,
‘same as usual’, ‘rather more than usual, or ‘much more
than usual’). It can be scored in a bimodal fashion (0–0–
1-1), when final scores range from 0 to 12. According to
this method, patients scoring 5 or more are considered: at
risk of anxiety/depression [10].
The validated Hungarian version of the abbreviated
sense of coherence (SOC-13) scale was used in the
present survey to measure the overall capacity to cope
with stressful situations. All 13 items are answerable on
a Likert scale from 1 to 7, total scores vary between 13
and 91. A higher score indicates stronger SOC [10].
The Perceived Stress Scale (PSS) is the most widely
used psychological instrument for measuring perception
of stress. Scores for the 4-item form range from 0 to 16.
Potential responses range from 0 (never) to 4 (very often)
and positively stated items are reverse coded before items
are summed up with higher scores indicating more per-
ceived stress [11].
The Dysfunctional Attitude Scale form A (DAS-A)
is designed to measure the presence and intensity of
dysfunctional attitudes. The higher the score, the more
dysfunctional attitudes are characteristic of an individ-
ual. The 17 items are divided into two subscales: per-
fectionism and dependency. Each item is scored on a
Likert scale from 1 to 7. Sum scores for either subscale
are calculated by simple addition [12].
Statistical analysis
Statistical analysis was performed using IBM SPSS 20 soft-
ware. Data are described by the mean, standard deviation
frequencies and percentages. Categorical variables were
compared between groups using chi-squared or Fisher’s
exact test, as appropriate. Continuous variables were eval-
uated by independent samples t-test, Mann-Whitney test
and ANOVA or Kruskal-Wallis test. Spearman’s correla-
tions were used measuring the relationship between two
variables. Significance level was set at p < 0.05. Multiple
logistic regression (backward Likelihood Ratio method)
was performed among HL survivors to identify predictors
of employment status Odds ratios (OR) with 95% confi-




A total of 163 adult HL survivors completed the survey.
19 persons were beyond retirement age of 65 years and
4 persons had unknown employment status who there-
fore were excluded from the subgroup analysis. Data of
140 HL survivors (71 females, 51%) of working age were
investigated and the characteristics of survivors are
presented in Tables 1 and 2. The mean ages of survi-
vors at the time of diagnosis were 32.13 ± 13.05 years
and at completion of the survey 44.82 ± 14.55 years.
57 survivors (41%) had mixed cell HL, which was the
most frequent histological subtype. 73 patients (53%) had
stage I-II and 65 patients (47%) stage III-IV HL. 68
survivors (49%) had baseline comorbidity (most common:
cardiovascular disease 11%, gastroenterological 10%, der-
matological 5%, musculoskeletal 5% and haematological
2% of patients). 95 patients (69%) had received ABVD
treatment, while 43 patients (31%) had received some
other type of chemotherapy. Radiation had been adminis-
tered to 103 patients (74%).
The most common treatment related long-term side
effects were examined in active vs. inactive groups:
cardiovascular disease 9 (10%) vs. 12 (25%) patients
(p = 0.026), pulmonary disease 7 (8%) vs. 6 (12%) pa-
tients, thyroid disease 23 (25%) vs. 17 (36%) patients
and post-irradiation skin disorder 4 (4%) vs. 4 (8%)
patients, respectively.
Employment status
The majority of HL survivors had been in early adult-
hood at the time of diagnosis. Hence, the most import-
ant goal for them is to return to normal life including
work after their lymphoma is cured. Employment at the
time of the survey was defined as crucial factor of nor-
mal life so the survivors were split into two subgroups
based on employment status: active (93 patients) and
inactive (47 patients, see Fig. 1). Age at diagnosis of HL
(p < 0.001), completion of the survey (p < 0.001), edu-
cational level (p = 0.017) and treatment-related long-
term side effects (p < 0.001) were significantly different
between the inactive and active subgroups as shown in
Table 2. Employed survivors were on average 10 years
younger at the time of the survey, they had their diag-
nosis 7.5 years earlier, almost twice as many of the had
college degrees, and half of them had treatment related
long-term side effects compared to the inactive group.
Odds ratios and 95% CI of inactive versus active em-
ployment status by HL survivors’ clinical data are pre-
sented in Fig. 2.
Mental health of survivors
Thirty-four survivors (25%) had caseness scores with
HADS anxiety and 14 (10%) with HADS depression.
However, means for HADS anxiety and depression, per-
ceived stress (PSS), stress-depression-anxiety (DAS total)
and perfection as a dysfunctional attitude (DAS perfec-
tion) were found to be significantly higher among in-
active HL survivors. 14 (10%) of HL survivors had
abnormal levels of distress with GHQ, but 5 times more
of them were inactive compared to the active ones. In
terms of sense of coherence as a measure of generalised
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coping resources, active survivors had significantly higher
mean score. With the exception of dependency, as a dys-
functional attitude, all other measures reflected consider-
ably less favourable mental health among those who had
been inactive. The results of mental health questionnaires
are shown in Table 3.
We defined severe mental vulnerability as having ab-
normal scores on at least 3 tests according to which
15 survivors (7 inactive, 5 active, 3 pensioners) were
identified as in urgent need of care. 2/3 of them (10
survivors) were referred to specialist (clinical psych-
ologist/psychiatrist). 5 persons referred to the team













Univariate analysis Multiple analysis
p ODDS 95% CI p ODDS 95% CI
Age at survey > = 40 yr. 76 (54%) 15 (32%) 61 (66%) <0.001 4.357 2.038–9.316
vs. <40 yr. 64 (46%) 32 (68%) 32 (34%)
Age at dg. > = 30 yr. 80 (57%) 16 (34%) 64 (69%) <0.001 4.276 2.028–9.016 0.001 3.556 1.548–8.168
vs. <30 yr. 60 (43%) 31 (66%) 29 (31%)
Elapsed time > =10 yr. 66 (47%) 24 (51%) 42 (45%) 0.436 1.325 0.652–2.689
vs. <10 yr. 74 (53%) 23 (49%) 51 (55%)
Male 69 (49%) 23 (49%) 46 (49%) 0.953 0.979 0.485–1.975
vs. female 71 (51%) 24 (51%) 47 (51%)
Residence: village 32 (23%) 12 (26%) 20 (22%) 0.592 1.252 0.507–2.062
vs. city 108 (77%) 35 (74%) 73 (78%)
Education level:
elementary 50 (36%) 24 (53%) 26 (28%) 0.014 3.346 1.282–8.734 0.032 3.320 1.112–9.914
vs. college 37 (27%) 14 (30%) 38 (41%)
elementary 0.568 1.336 0.494–3.609 0.235 1.967 0.644–6.007
vs. high school 52 (37%) 8 (17%) 29 (31%)
Single 68 (50%) 23 (52%) 45 (49%) 0.714 1.144 0.557–2.347
vs. live together 68 (50%) 21 (48%) 47 (51%)
Stage 3–4 73 (53%) 24 (52%) 41 (45%) 0.399 1.357 0.668–2762
vs. 1–2 65 (47%) 22 (48%) 51 (55%)
Bulk 42 (32%) 11 (27%) 31 (34%) 0.409 0.710 0.314–1.605
vs. without bulk 90 (68%) 30 (73%) 60 (66%)
B symptom 61 (46%) 20 (49%) 41 (44%) 0.691 1.161 0.555–2.433
vs. no B symptom 71 (54%) 21 (51%) 50 (56%)
ECOG 1–2 22 (17%) 8 (20%) 14 (16%) 0.593 1.299 0.497–3.390
vs. ECOG 0 108 (83%) 33 (80%) 75 (84%)
Comorbidity 68 (49%) 25 (53%) 43 (44%) 0.437 1.321 0.654–2.667
vs. no comorbidity 72 (51%) 22 (47%) 50 (56%)
Treatment: ABVD 43 (31%) 16 (34%) 27 (30%) 0.599 1.224 0.576–2.597
vs. other 95 (69%) 31 (66%) 64 (70%)
Irradiation 103 (74%) 35 (74%) 68 (73%) 0.864 1.072 0.482–2.387
vs. no irradiation 37 (26%) 12 (26%) 25 (27%)
Treatment response: PR 72 (51%) 4 (9%) 5 (5%) 0.484 1.637 0.418–6.409
vs. SD 68 (49%) 43 (81%) 88 (95%)
Treatment related side effect: yes 72 (51%) 36 (77%) 36 (39%) <0.001 5.182 2.343–11.460 <0.001 5.254 2.196–12.524
vs. no 68 (49%) 11 (23%) 57 (61%)
Relapse 21 (15%) 7 (15%) 14 (15%) 0.980 0.983 0.369–2.641
vs. no relapse 119 (85%) 40 (85%) 79 (85%)
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Fig. 1 Survivors’ employment status at completion of survey (organogram)
Fig. 2 ORs and 95% CI of inactive vs. active employment status by clinical data in HL survivors of working age. The analysis was performed by
binary logistic regression. Values under 1 are related to the active employment status, above 1 to inactive employment status
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psychologist. Subsequently, 3 of the 7 inactive patients
returned to work.
Independent predictive factors for employment status
Multiple logistic regression analysis was carried out by
starting with all potential determinant variables and
eliminating the non-significant ones. Significant differ-
ences between inactive and active groups were found
regarding (being at least or over ≥30 year vs. below) at
diagnosis (p = 0.001), education level (elementary
school or above vs. college, p = 0.032) and treatment
related long-term side effects (yes vs. no, p < 0.001;
Table 2).
Predictive factors for treatment related long-term side
effects
Predictive factors for treatment related long-term side
effects are presented in Table 4. Females had a higher
rate of treatment-related long-term side effects com-
pared to males (p = 0.011), those on ABVD regimen
suffered more side effects compared to those who had
received other regimens (p < 0.001). Relapse rate
(p = 0.003) and baseline comorbidities (p < 0.001) were
significantly higher among female survivors (71 patients)
(not shown). Independent variables of treatment-related
long-term side effects are female gender (OR: 2.67 (95%
CI 1.327–5.375); p = 0.006) and other regimens than
ABVD (OR: 6.17 (95% CI 2.788–13.655); p < 0.001).
Loss of work after HL treatment
There were 13 survivors in the active group, who lost
their work after treatment but later found new jobs. 20
survivors became inactive due to job loss in the inactive
group of whom 17 persons as opposed to only 5 of the
13 in the active group had treatment-related long-term
Table 3 Quality of Life questionnaires for survivors
All patients (n = 140) Inactive(I) (n = 47) Active(A) (n = 93) P (I-A)
Mean ± SD
HADS anxiety 5.46 ± 3.54 6.69 ± 3.64 4.87 ± 3.35 0.004
HADS depression 3.05 ± 3.19 4.87 ± 3.84 2.17 ± 2.38 <0.001
PSS 4.55 ± 2.80 5.93 ± 2.83 3.87 ± 2.53 <0.001
SOC 66.90 ± 11.26 62.55 ± 69.03 69.03 ± 10.51 0.002
DAS total 49.35 ± 18.94 54.79 ± 22.01 46.80 ± 16.86 0.022
DAS perfection 28.41 ± 12.61 31.98 ± 14.94 26.74 ± 11.07 0.024
DAS dependency 20.94 ± 8.01 22.81 ± 8.35 20.07 ± 7.74 0.063
Number of patients (%)
HADS anxiety
normal score: 0–7 104 (75%) 26 (57%) 78 (84%) 0.004
borderline: 8–11 21 (15%) 12 (27%) 9 (10%)
abnormal: 11–21 13 (10%) 7 (16%) 6 (6%)
HADS depression
normal score: 0–7 124 (90%) 35 (78%) 89 (96%) 0.005
borderline: 8–10 8 (6%) 6 (13%) 2 (2%)
abnormal: 11–21 6 (4%) 4 (9%) 2 (2%)
GHQ
normal score: 0–4 124 (90%) 35 (78%) 89 (96%) 0.002
abnormal: ≥5 14 (10%) 10 (22%) 4 (4%)
HADS Hospital Anxiety and Depression scale, GHQ General Health Questionnaire, PSS Perceived Stress, Scale, SOC Sense of Coherence Scale, DAS Dysfunctional
Attitude Scale









Male (n = 69) 28 (41%) 41 (59%) 0.011
Female (n = 71) 44 (62%) 27 (38%)
Chemotherapy
A(E)BVD (n = 95) 38 (40%) 57 (60%) <0.001
Other than ABVD
(n = 43)
33 (77%) 10 (23%)
A(E)BVD: adriamycin, (epirubicin), bleomycin, vinblastine and dacarbazine;
Other than ABVD: CV(O)PP:cyclophosphamide, vinblastine [vincristine],
procarbazine and prednisolone; COPP/ABV:cyclophosphamide, vincristine,
procarbazine, prednisolone/adriamycin, bleomycin and vinblastine
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side effects (p = 0.009). These results are presented in
Fig. 3.
Discussion
The cure of Hodgkin lymphoma is one of the success stor-
ies of cancer medicine in the twentieth century. This re-
sulted in a continuously growing number of HL survivors
at risk for long-term sequel and quality impairment in
their lives. The majority of HL survivors have been in early
adulthood so their most important goal is to return to
normal life once their disease is cured [7]. Work is a crit-
ical aspect of normal life so our study investigated long-
term HL survivors by their employment status, excluding
those over retirement age (65 years).
Two-third of our survivors was active at the completion
of the survey. They had been significantly younger at the
time of HL diagnosis as well as at the completion of the
survey; they had higher educational level, and less
treatment-related long-term side effects compared to in-
active survivors. Neither gender, nor characteristics of the
disease at the time of diagnosis were found to be different
between the active and inactive groups. HL survivors’ em-
ployment status varies from 71% to 85% [14–17]; our data
are close to the lower end of this range. Hungarian HL
survivors have other options regarding work after treat-
ment. 25% of all participants became disability pensioners
that provide a steady albeit low income, a definitive
advantage compared to employment for some patients.
Unemployment rate in the adult population of the country
according to data of the Hungarian Central Statistical
Office (available at: https://www.ksh.hu/) was 7.2% in the
North-eastern region of Hungary (for 2012 to 2015,
among 40–49 age group, both gender), almost 1.5 times
higher than in our study population (5%). In contrast, the
ratio of inactive persons was 1.5 times higher among HL
survivors (21% vs. 14.5%). (Both groups are of working
age, but unemployed persons search for work and regis-
tered as such, inactive persons do not search for work.)
In light of the fact that the proportion of disabled HL
survivors varies from 9% in Sweden [17] to 19% in
Denmark [18], more effort needs to be put into helping
Hungarian patients find their way back to work. Employ-
ment status, the mental health of long-term survivors of
cancer (lymphoma) should also be a focus for research.
Our study used various tools to investigate the mental
status of HL survivors; a strong correlation was observed
between employment status and psychological well-
being. Active (working) survivors were significantly less
depressed, less anxious, less perfectionist than their
inactive peers; they proved to be much more resilient as
reflected by their sense of coherence; and correspond-
ingly, only one-fifth of them were pathologically dis-
tressed compared to the inactive ones.
The majority of cured HL patients survive without psy-
chological distress at case level with HADS questionnaire
[19]. Previous studies of anxiety and depression in lymph-
oma patients using HADS observed prevalence of anxiety
between 15 and 42%, and depression between 4 and 35%
[20]. The prevalence of anxiety and depression were 25%
and 10% using HADS in our study population, well within
the range of other studies. So far there have been few
published data with GHQ for haematological disorders.
Broers et al. reported results for patients 3 years after bone
marrow transplant among whom 13% showed mental
stress by the GHQ, a percentage comparable to that in the
general population [21]. Harila et al. [22] found no differ-
ence in GHQ scores between long-term ALL survivors
and controls. Our experience revealed that 10% of HL
survivors had abnormal levels of distress with GHQ, with
a much lower proportion among working survivors. Our
findings with the SOC questionnaire are similar to those
of Wettergren et al. [23] who found a mean of SOC
(66.8 ± 11.2) in the Swedish population that was almost
identical to the mean of our patients. There are no litera-
ture data with DAS and PSS scales in haematological
disorders.
Fig. 3 Loss of work after lymphoma treatment by patient reports
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Five previous studies with clinical data (four of them
questionnaire-based) investigated employment specific-
ally in HL survivors. Fobair et al. reported in 1986 that
male gender, depression, age at or over 30 years, energy
loss, and current disease status correlated with the num-
ber of hours worked. Neither stage nor treatment type
predicted time to return work [14]. Abrahamsen pub-
lished data in 1998on HL survivors’ employment status
according to which 95% of 557 patients treated be-
tween1971–1991 had returned to work after 18 months.
Female predominance was observed among unemployed
survivors during the follow-up period (64% of women
and 85% of men worked after 18 months of the start of
treatment) [24]. Chen et al. reported that male gender
and scarring of the head and neck were risk factors for
having been denied a job due to medical history [15].
Glimelius et al. highlighted in 2015 that advanced stage
HL survivors treated with full-dose chemotherapy were
at risk of work loss which was not explained by relapsed
disease, secondary malignancies or cardiovascular dis-
ease [17]. Behringer et al. published favourable data on
social reintegration and treatment outcome among HL
survivors. Their analysis revealed a significant negative
association of severe fatigue (sFA) and employment sta-
tus in survivors: 5 years after therapy, 51% and 63% of
female and male survivors, respectively, with sFA had
been in employment or in professional education, com-
pared with 78% and 90% without sFA, respectively
(p < 0.001) [25].
According to our data, lower age at diagnosis, college-
level education, and no treatment-related long-term side
effects are independent predictive factors for employment
after treatment comes to an end. The risks factors of
treatment-related long-term side effects are female gender,
chemotherapy other than ABVD. The reduction of dose
and field of radiation therapy and the application of ABVD
regimen had become more tailored for HL treatment that
might have led to the reduction of treatment-related long-
term side effects which became apparent in our study
population after 2002. Treatment-related long-term side
effects had a clearly negative impact on inactive employ-
ment status. According to our results, the frequency of
cardiovascular disease is significantly higher among in-
active survivors.
Conclusion
Our data suggest that employment status, education
and treatment-related long-term side effects (hypothyr-
eodism, cardiomyopathy, coronary sclerosis, valvulopathy,
pulmonary fibrosis, postirradiation skin and muscle atro-
phy) play a critical role in the quality of life of HL survi-
vors. In order to help HL patients become not only
survivors but fully functioning, cured persons capable
of working, the further development of target-specific
therapeutic modalities (anti-CD30 targeting with
brentuximab-vedotin, programmed death 1 (PD-1)
blockers) is needed along with clinical studies that in-
clude follow-up measurements of quality of life.
A growing number of studies provide evidence for the
necessity of work rehabilitation after the cure of cancer
(among them Hodgkin-lymphoma). Denmark has a wide-
spread tax-financed welfare system which provides an
option for persons with permanently reduced work cap-
acity to retire due to their disability and be financially
compensated [18]. In Sweden, multidisciplinary inter-
ventions promote a healthy work environment/lifestyle
involving physical, psychological, and vocational com-
ponents [17]. Social reintegration program has also
been available for oncological patients in Hungary.
However, the Hungarian follow-up guidelines do not
include recommendations for work rehabilitation pro-
gram of HL survivors. Based on our investigation, we
suggested an extended social reintegration program for
Hungarian HL patients also. A clinical psychologist as
member of our haematological team provides psycho-
logical support to patients in our department. There
exists an active Lymphoma Civil Patient Forum that
provides numerous opportunities to increase our pa-
tients’ psychological well-beeing. Control examinations
create time for encounters between haematologist and
patients during which psychological guidance facilitates
HL survivors to step out of the patient role.
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